• Title of article

    Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure

  • Author/Authors

    Takayoshi Tsutamoto، نويسنده , , Atsuyuki Wada، نويسنده , , Keiko Maeda، نويسنده , , Naoko Mabuchi MD، نويسنده , , Masaru Hayashi، نويسنده , , Takashi Tsutsui، نويسنده , , Masato Ohnishi، نويسنده , , Masahide Sawaki MD، نويسنده , , Masanori Fujii، نويسنده , , Takehiro Matsumoto، نويسنده , , Toshiki Matsui، نويسنده , , Masahiko Kinoshita، نويسنده ,

  • Issue Information
    روزنامه با شماره پیاپی سال 2001
  • Pages
    6
  • From page
    1228
  • To page
    1233
  • Abstract
    OBJECTIVES We sought to evaluate the effects of spironolactone on neurohumoral factors and left ventricular remodeling in patients with congestive heart failure (CHF). BACKGROUND Aldosterone (ALD) promotes collagen synthesis and structural remodeling of the heart. Spironolactone, an ALD receptor antagonist, is reported to reduce mortality in patients with CHF, but its influence on left ventricular remodeling has not been clarified. METHODS Thirty-seven patients with mild-to-moderate nonischemic CHF were randomly divided into two groups that received treatment with spironolactone (n = 20) or placebo (n = 17). We measured left ventricular volume and mass before treatment and after four months of treatment. We also measured the plasma levels of neurohumoral factors, such as atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), as well as plasma procollagen type III aminoterminal peptide (PIIINP), a marker of myocardial fibrosis. RESULTS Left ventricular volume and mass were significantly decreased and ejection fraction was significantly increased in the spironolactone group, while there were no changes in the placebo group. Plasma levels of ANP, BNP and PIIINP were significantly decreased after spironolactone treatment, but were unchanged in the placebo group. There was a significant positive correlation between the changes of PIIINP and changes of the left ventricular volume index (r = 0.45, P = 0.045) as well as the left ventricular mass index (r = 0.65, P = 0.0019) with spironolactone treatment. CONCLUSIONS These findings indicate that four months of treatment with spironolactone improved the left ventricular volume and mass, as well as decreased plasma level of BNP, a biochemical marker of prognosis and/or ventricular hypertrophy, suggesting that endogenous aldosterone has an important role in the process of left ventricular remodeling in nonischemic patients with CHF.
  • Keywords
    angiotensin-converting enzyme , plasma active renin concentration , atrial natriuretic peptide , procollagen type III aminoterminal peptide , ANP , PIIINP , Aldosterone , Randomized Aldactone Evaluation Study , Congestive heart failure , BNP , ethylenediaminetetraacetic acid , left ventricular ejection fraction , EDTA , ACE , PARC , NYHA , ALD , RALES , New York Heart Association , CHF , LVEF , brain natriuretic peptide
  • Journal title
    JACC (Journal of the American College of Cardiology)
  • Serial Year
    2001
  • Journal title
    JACC (Journal of the American College of Cardiology)
  • Record number

    596503